Top news of the week: 30.11.2021.
Healthcare
Gene Therapy Firm's Shares Rise 120% on Topline Data from Pivotal Dystrophic EB Study
Shares of Krystal Biotech Inc. reached a new 52-week high after the company reported it met both primary and secondary endpoints in its pivotal GEM-3 trial of VYJUVEK™ in patients diagnosed ...
Clinical Catch-Up: November 22-26
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
Money on the Move: November 17 – 23
Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash.
Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant
Omicron-specific vaccine being pursued in parallel –
Alnylam is getting a rare kind of leader
Yvonne Greenstreet, named John Maraganore’s successor, will become one of few Black women to lead a drug company.
Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them.
After several family members had early heart attacks, Kathiresan vowed to understand why they happen. His research journey has changed medical practice and led to a new biotech startup, ...
Gene-Based Therapy for Rare Skin Disease Succeeds in Phase III
Results from its GEM-3 trial on VYJUVEK demonstrated statistical significance in its ability to promote complete wound healing within six months compared to a placebo.
Omicron Variant has Vaccine Makers Moving Fast and More COVID News
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue ...